MOUNTAIN VIEW, Calif., Nov 24, 2003 /PRNewswire-FirstCall via Comtex/ -- IMPAC Medical Systems, Inc. (Nasdaq: IMPC) and IMPATH Inc. (OTC: IMPHQ.PK) announced today that they have entered into a definitive asset purchase agreement under which IMPAC will acquire substantially all of the assets and certain liabilities of Tamtron Corporation and Medical Registry Services, Inc., IMPATH's PowerPath(R) pathology information management and cancer registry information system businesses. The transaction is valued at approximately $22 million in cash and the assumption of certain liabilities.

"We look forward to adding the PowerPath(R) pathology information management system to the IMPAC product line. We have always viewed this area as a synergistic adjacency to our core oncology management business. Seventy percent of all cases pathologists see are cancer-related and their analysis constitutes the first point in a long chain of cancer information management," stated Joseph K. Jachinowski, president and CEO of IMPAC.

Jachinowski added, "This acquisition would also further expand IMPAC's presence in the cancer registry market, allowing us to more efficiently deliver higher quality products to our customers and to add a significant number of cases to our National Oncology Database."

IMPATH chose IMPAC as the "stalking horse" bidder after conducting an extensive marketing process with other potential acquirers. Carter Eckert, IMPATH's Chairman and Chief Executive Officer, stated, "We are pleased to have entered into this agreement with IMPAC. This agreement significantly furthers our efforts to have all of the operating businesses of IMPATH emerge from Chapter 11 at the earliest possible date. We believe this transaction provides the opportunity to deliver value to our economic stakeholders as well as continued support and service to PowerPath(R) and cancer registry clients."

IMPATH, Tamtron Corporation and Medical Registry Services, Inc. are operating as debtors-in-possession under the Bankruptcy Code, after having commenced a chapter 11 case on September 28, 2003 in the U.S. Bankruptcy Court for the Southern District of New York. This asset sale will be conducted under Section 363 of the Code. The transaction is subject to Bankruptcy Court approval of IMPAC as the stalking horse bidder in a competitive auction process and other customary closing conditions. IMPATH will file the agreement with the Bankruptcy Court on November 24, 2003 and will ask the Bankruptcy Court to approve the bid and auction procedures. Pending approvals, the sale is expected to be completed in approximately 30 to 45 days, unless a superior offer is received in the auction.

Asante Partners LLC is acting as financial advisor to IMPATH with respect to the sale of Tamtron Corporation and Medical Registry Services.

About IMPAC Medical Systems Inc.

IMPAC Medical Systems, Inc. is a leading provider of specialized IT solutions that streamline both clinical and business operations to help improve the process of delivering quality patient care. With open integration to multiple healthcare data and imaging systems, IMPAC offers a comprehensive IT solution that includes specialized electronic charting, full-featured practice management, clinical laboratory management, and outcomes reporting. Supporting over 1,600 installations worldwide, IMPAC delivers practical solutions that deliver better overall communication, process efficiency and quality patient care. For more information about IMPAC Medical Systems' products and services, please call 650-623-8800 or visit www.impac.com.

About IMPATH Inc.

IMPATH is in the business of improving outcomes for cancer patients. The Company is a leading source of cancer information and analyses with a database of over 1 million patient profiles and outcomes data on more than 2.3 million individuals. IMPATH Physician Services uses sophisticated technologies to provide patient-specific cancer diagnostic and prognostic information to more than 8,700 pathologists and oncologists in over 2,100 hospitals and 630 oncology practices. Utilizing its comprehensive resources, IMPATH Predictive Oncology serves genomics, biotechnology and pharmaceutical companies involved in developing new therapeutics targeted to specific, biological characteristics of cancer. IMPATH Information Services provides software products, including PowerPath(R) and the IMPATH Cancer Registry(TM) for the collection and management of diagnostic data and outcomes information. The Company's software products are currently being utilized in nearly 1,000 hospitals, academic centers and independent laboratories across the country.

The statements contained in this press release that are not purely historical are forward looking statements within the meaning of Section 27A of the Securities and Exchange Act of 1933, including statements regarding each company's expectations, beliefs, hopes, intentions or strategies regarding the future. Forward looking statements include statements regarding the proposed acquisition, each company's business strategy, timing of, and plans for, the introduction of new products and enhancements, future sales, market growth and direction, competition, market share, revenue growth, operating margins and profitability. All forward-looking statements included in this document are based upon information available to each company as of the date hereof, and neither company assumes any obligation to update any such forward-looking statement. Actual results could differ materially from current expectations as a result of known and unknown risks and uncertainties. Factors that could cause or contribute to such differences include the fact that another party could outbid IMPAC in the bankruptcy auction, IMPAC's ability to expand outside the radiation oncology market or expand into international markets, lost sales or lower sales prices due to competitive pressures, ability to integrate its products successfully with related products and systems in the medical services industry, reliance on distributors and manufacturers of oncology equipment to market its products, and other factors and risks discussed in reports filed by each company from time to time with the Securities and Exchange Commission.

In addition to the foregoing, additional factors could include the outcome of IMPATH's chapter 11 case, including any restructuring or reorganization efforts, risks inherent in IMPATH's chapter 11 process, results of the current investigation into accounting irregularities and discrepancies at IMPATH and the outcome of any legal proceeding or any SEC investigation relating to IMPATH.

    CONTACT:

     Joseph K. Jachinowski
     President and Chief Executive Officer
     IMPAC Medical Systems
     650-623-8800
     ir@impac.com

     Iris D. Daniels
     Investor Relations
     IMPATH Inc.
     212-698-0300
     idaniels@impath.com

     S. Jennifer Lloyd
     Managing Director
     Asante Partners
     650-566-9364

SOURCE IMPAC Medical Systems, Inc.

Joseph K. Jachinowski, President and Chief Executive Officer of
IMPAC Medical Systems, +1-650-623-8800, or ir@impac.com; or Iris D. Daniels,
Investor Relations of IMPATH Inc., +1-212-698-0300, or idaniels@impath.com; or
S. Jennifer Lloyd, Managing Director of Asante Partners, +1-650-566-9364

http://www.prnewswire.com